From GlobeNewswire: 2025-05-14 16:32:00

SS Innovations International, Inc. reported record quarterly revenue of $5.1 million, a 40.8% increase from the first quarter of 2024. Gross margin also improved to 21.23%, with a net loss of $5.7 million. SSi Mantra surgical robotic system installations totaled 15, a 66.7% increase from the previous year. The company has filed a quarterly report with the SEC and plans to submit a De Novo application to the FDA for SSi Mantra 3 by July 2025. The SSi Mantra system has received regulatory approvals in the Philippines and Ukraine, showcasing the company’s commitment to global expansion.

In the first quarter of 2025, SS Innovations achieved record revenue driven by higher unit sales of the SSi Mantra 3 system. With an expanding installed base and growing utilization, the company is poised for continued growth. After uplisting to Nasdaq, SS Innovations plans to pursue approval in the EU and US. The company aims to democratize robotic surgery by deploying cost-effective SSi Mantra 3 devices globally. The SSi Mantra system has been clinically validated in over 100 surgical procedures, showcasing its versatility and effectiveness.

Financially, SS Innovations reported $15.9 million in cash and cash equivalents, with a total of 78 SSi Mantra systems installed and 3,568 cumulative surgeries as of March 31, 2025. The company’s strategic approach to innovation and expansion highlights its potential for continued success in the field of surgical robotics.



Read more at GlobeNewswire: SS Innovations Reports First Quarter 2025 Financial